Sichuan Baili Pharmaceutical

688506 · SSE STAR Market

Public Market Listing

688506SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Sichuan Baili Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
0Approved
3Phase 3 / Filed
6Phase 1–2 / Early
11Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Phase 3
EGFR + HER3Multispecific antibody
Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaEsophageal Cancer
Esophageal Squamous Cell Carcinoma
Phase 3
EGFR + HER3Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerOvarian CancerBiliary Tract CancerBladder / Urothelial CancerNasopharyngeal CarcinomaEsophageal Cancer
HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma, Esophageal Squamous Cell Carcinoma
Phase 3
HER2Antibody–drug conjugate
Non-Small Cell Lung CancerOvarian CancerColorectal CancerBiliary Tract CancerBreast CancerBladder / Urothelial Cancer
HER2-Positive Breast Cancer, Urothelial Carcinoma
Phase 2
Undisclosed / early pipelineAntibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 2
PD-1 x CTLA-4Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2
TROP2Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
ROR1 (plus T-cell engaging costimulatory components)Multispecific antibody
Acute Myeloid LeukemiaChronic Lymphocytic Leukemia
Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1
Undisclosed / early pipelineAntibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
CD3 x tumor antigen x immune checkpoint (multi-specific)Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(67 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (22)
November 2026 (2)
Danvilostomig + IzalontamabPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2026-11 · NCT06668961 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Nasopharyngeal Carcinoma
Est. primary completion 2026-11 · NCT06118333 · CT.gov ↗
What to watch
December 2026 (20)
Danvilostomig + IzalontamabPhase 1/2Squamous Cell Carcinoma of Head and Neck
Est. primary completion 2026-12 · NCT05668858 · CT.gov ↗
What to watch
Danvilostomig + IzalontamabPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT05949606 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06114511 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 1/2Gynecological Malignant Tumor, Solid Tumor
Est. primary completion 2026-12 · NCT05803018 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 1/2Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Est. primary completion 2026-12 · NCT06031584 · CT.gov ↗
What to watch
NebratamigPhase 1/2Non-hodgkin's Lymphoma
Est. primary completion 2026-12 · NCT06066203 · CT.gov ↗
What to watch
IzalontamabPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2026-12 · NCT05054439 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Urinary System Tumor, Solid Tumor
Est. primary completion 2026-12 · NCT05785039 · CT.gov ↗
What to watch
Izalontamab brengitecan + DanvilostomigPhase 2Small Cell Lung Cancer
Est. primary completion 2026-12 · NCT05924841 · CT.gov ↗
What to watch
Izalontamab brengitecan + DanvilostomigPhase 2Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
Est. primary completion 2026-12 · NCT05956587 · CT.gov ↗
What to watch
Izalontamab brengitecan + DanvilostomigPhase 2Urothelial Carcinoma, Solid Tumor
Est. primary completion 2026-12 · NCT05965856 · CT.gov ↗
What to watch
Izalontamab brengitecan + DanvilostomigPhase 2Cervical Cancer
Est. primary completion 2026-12 · NCT05990803 · CT.gov ↗
What to watch
Izalontamab brengitecan + DanvilostomigPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2026-12 · NCT06006169 · CT.gov ↗
What to watch
Izalontamab brengitecan + DanvilostomigPhase 2Esophageal Cancer, Gastric Cancer, Colorectal Cancer
Est. primary completion 2026-12 · NCT06008054 · CT.gov ↗
What to watch
Est. primary completion 2026-12 · NCT06042894 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Urothelial Carcinoma
Est. primary completion 2026-12 · NCT06405425 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Extensive-stage Small-cell Lung Cancer
Est. primary completion 2026-12 · NCT06437509 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Triple-negative Breast Cancer
Est. primary completion 2026-12 · NCT06471205 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06382129 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06500026 · CT.gov ↗
What to watch
2027 (17)
January 2027 (1)
Trastuzumab brengitecanPhase 1/2Gynecological Malignancies
Est. primary completion 2027-01 · NCT06131450 · CT.gov ↗
What to watch
May 2027 (5)
Izalontamab brengitecanPhase 2Renal Cancer
Est. primary completion 2027-05 · NCT06962787 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Advanced Biliary Tract Cancer
Est. primary completion 2027-05 · NCT06978114 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Advanced Hepatocellular Carcinoma
Est. primary completion 2027-05 · NCT06986785 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Cervical Cancer, Endometrial Cancer
Est. primary completion 2027-05 · NCT07054567 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 3HER2-low Breast Cancer
Est. primary completion 2027-05 · NCT06957886 · CT.gov ↗
What to watch
June 2027 (7)
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-06 · NCT06498986 · CT.gov ↗
What to watch
Est. primary completion 2027-06 · NCT06787664 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2027-06 · NCT06437522 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
Est. primary completion 2027-06 · NCT06475300 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Urothelial Carcinoma
Est. primary completion 2027-06 · NCT06857175 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2027-06 · NCT06994195 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 3Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-06 · NCT07152405 · CT.gov ↗
What to watch
July 2027 (1)
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-07 · NCT05880706 · CT.gov ↗
What to watch
December 2027 (3)
Trastuzumab brengitecanPhase 2Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2027-12 · NCT07264816 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 3Colorectal Cancer
Est. primary completion 2027-12 · NCT07730489 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 3Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2027-12 · NCT07178795 · CT.gov ↗
What to watch
2028 (15)
March 2028 (1)
Izalontamab brengitecanPhase 2/3Breast Neoplasms
Est. primary completion 2028-03-13 · NCT06926868 · CT.gov ↗
What to watch
December 2028 (14)
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2028-12 · NCT07827261 · CT.gov ↗
What to watch
BL-M09D1Phase 2Gynecological Malignancies, Solid Tumors
Est. primary completion 2028-12 · NCT07769229 · CT.gov ↗
What to watch
BL-M09D1Phase 2Urothelial Carcinoma (UC), Solid Tumors
Est. primary completion 2028-12 · NCT07837622 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 2Breast Cancer
Est. primary completion 2028-12 · NCT07678957 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Castration-resistant Prostate Cancer
Est. primary completion 2028-12 · NCT07641855 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Esophageal Squamous Cell Carcinoma
Est. primary completion 2028-12 · NCT07554456 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 2/3HER2-positive Breast Cancer
Est. primary completion 2028-12 · NCT06891833 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2028-12 · NCT06838273 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 3Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2028-12 · NCT07545460 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Biliary Tract Cancer
Est. primary completion 2028-12 · NCT07582315 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Breast Cancer
Est. primary completion 2028-12 · NCT07648914 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 3Biliary Tract Cancer
Est. primary completion 2028-12 · NCT07606599 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Non-Small Cell Lung Cancer
Est. primary completion 2028-12-15 · NCT07100080 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-12-29 · NCT06855771 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Izalontamab brengitecanPhase 2/3Urothelial Cancer
Est. primary completion 2029-01-26 · NCT07106762 · CT.gov ↗
What to watch
December 2029 (5)
Izalontamab brengitecanPhase 2/3Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2029-12 · NCT07739186 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Squamous Non-small-cell Lung Cancer
Est. primary completion 2029-12 · NCT07739199 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-12 · NCT07502300 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Triple-Negative Breast Cancer (TNBC)
Est. primary completion 2029-12 · NCT07729956 · CT.gov ↗
What to watch
Trastuzumab brengitecanPhase 3HER2-positive Breast Cancer
Est. primary completion 2029-12 · NCT07518173 · CT.gov ↗
What to watch
2030 (2)
December 2030 (2)
Izalontamab brengitecanPhase 2Nasopharyngeal Carcinoma (NPC)
Est. primary completion 2030-12 · NCT07797881 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Non-small Cell Lung Cancer Stage III
Est. primary completion 2030-12 · NCT07640789 · CT.gov ↗
What to watch
2031 (3)
February 2031 (1)
Izalontamab brengitecanPhase 1/2Lung Cancer, Breast Cancer
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
October 2031 (1)
Trastuzumab brengitecanPhase 3HER2-positive Breast Cancer
Est. primary completion 2031-10 · NCT06830889 · CT.gov ↗
What to watch
December 2031 (1)
Izalontamab brengitecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2031-12-30 · NCT07680790 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Izalontamab brengitecanPhase 2/3Non-small Cell Lung Cancer
Est. primary completion 2032-12 · NCT07642024 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Izalontamab brengitecanPhase 3Nasopharyngeal Carcinoma (NPC)
Est. primary completion 2033-12 · NCT07783321 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026Filing acceptedIzalontamab brengitecanChina accepts new drug applications for iza-bren in triple-negative breast cancer and non-small cell lung cancer
CN, NMPA · Sichuan Baili Pharmaceutical · Source ↗
26 February 2026Topline resultIzalontamab brengitecanPhase III BL-B01D1-307 interim topline: iza-bren met dual primary endpoints (PFS and OS) in TNBC
CN · Sichuan Biokin Pharmaceutical (SystImmune parent) · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1——$430M—report ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$351M$350M—$147Mreport ↗

Sichuan Baili Pharmaceutical reported revenue of $350.85M, down 56.7% YoY, R&D spend of $350M, up 74.3% YoY, and a quarterly net burn of $146.68M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$810M$201M——report ↗
2023-FY$80M$106M—$110Mreport ↗
2022-FY—$56M——report ↗